STOCK TITAN

Codexis Inc. - CDXS STOCK NEWS

Welcome to our dedicated news page for Codexis (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Codexis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Codexis's position in the market.

Rhea-AI Summary
Stephen Dilly, CEO of Codexis, named finalist for 2023 Bloom Burton Award
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. to attend Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.57%
Tags
conferences
-
Rhea-AI Summary
Codexis, Inc. executes lease assignment, resulting in estimated cash savings of over $30M through 2031
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
Codexis, Inc. plans to prioritize the advancement and commercialization of its ECO Synthesis™ platform for RNAi therapeutics production. The company will streamline operations, discontinue certain development programs, and reduce headcount by 25%. Codexis expects to have sufficient funds to support its operations until mid-2026. The company also expects its Pharmaceutical Manufacturing business to return to growth in 2024. Preliminary unaudited revenue for the second quarter of 2023 is expected to be in the range of $21 million to $22 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.07%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
none
Codexis Inc.

Nasdaq:CDXS

CDXS Rankings

CDXS Stock Data

201.77M
63.61M
3.22%
82.74%
3.39%
Paint and Coating Manufacturing
Manufacturing
Link
US
Portland

About CDXS

codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop